CCR10
趋化因子受体
CCR1
CCL21型
嵌合抗原受体
癌症研究
趋化因子受体CCR5
趋化因子受体
趋化因子
趋化因子受体
CXCL2型
C-C趋化因子受体6型
CCL18型
CCL7型
免疫学
生物
T细胞
免疫系统
作者
Pengfei Zhang,Chuang Wang,Le Zhang,Li Xin Qiu
出处
期刊:Immunotherapy
[Future Medicine]
日期:2022-04-01
卷期号:14 (6): 459-473
被引量:3
标识
DOI:10.2217/imt-2021-0228
摘要
Currently, the antitumor efficacy of chimeric antigen receptor T cells in solid tumors is modest. Both chemokines and their receptors play a key role in the proliferation of cancer cells, tumor angiogenesis, organ-selective metastasis and migration of immune cells to solid tumors. Unfortunately, frequent chemokine/chemokine receptor 'mismatch' between effector cells and the tumor microenvironment results in inefficient T-cell infiltration and antitumor efficacy. Thus, reversing the 'mismatch' of chemokines and chemokine receptors appears to be a promising method for promoting T-cell infiltration into the tumor and enhancing their antitumor efficacy. In this review, we discuss functions of the chemokine/chemokine receptor axis in cancer immunity and the current understanding, challenges and prospects for improving the effect of chimeric antigen receptor T cells by reversing the mismatch between chemokines and chemokine receptors.Chimeric antigen receptor T (CAR-T) cell therapy is emerging as a promising therapeutic approach for cancers in the blood. The success of CAR-T cells has also sparked interest in applying this strategy to solid tumors; however, attempts have been disappointing, with only a few patients achieving a partial response. The chemokine/chemokine receptor axis plays a key role in the growth and spread of tumors. Unfortunately, chemokines and chemokine receptors in immune cells and the environment surrounding the tumor do not always match, which results in inefficient immune cell trafficking and infiltration. Therefore, reversing the ‘mismatch’ of chemokines and chemokine receptors appears to be a promising method for potential treatment. In this review, we discuss functions of the chemokine/chemokine receptor axis in cancer immunity and the current understanding, challenges and prospects for improving CAR-T cell therapy by reversing this mismatch.
科研通智能强力驱动
Strongly Powered by AbleSci AI